[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637371":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":62,"collaborators":32,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":32,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":32,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Mabwell (Shanghai) Bioscience Co., Ltd.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"9MW3811 Injection (Low Dose)","EXPERIMENTAL","Intravenous infusion, multiple doses administered according to the protocol",[13],"Drug: 9MW3811 Injection",{"label":15,"type":10,"description":11,"interventionNames":16},"9MW3811 Injection (Middle Dose)",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"9MW3811 Injection (High Dose)",[13],{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo","PLACEBO_COMPARATOR","Intravenous infusion, matching placebo administered on the same schedule",[25],"Drug: Placebo",[27,33],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","9MW3811 Injection","9MW3811 is a recombinant humanized monoclonal antibody targeting interleukin-11 (IL-11). It is administered intravenously.",[18,9,15],null,{"type":28,"name":21,"description":34,"armGroupLabels":35,"otherNames":32},"Matching placebo solution with no active ingredient, administered intravenously.",[21],[37],{"name":38,"role":39,"phone":40,"phoneExt":32,"email":41},"Liecheng Yang","CONTACT","021-58585793","liecheng.yang@mabwell.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine","RECRUITING","Shanghai","Shanghai Municipality","200011","China","CN",{"type":52,"coordinates":53},"Point",[54,55],121.45806,31.22222,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":32,"email":61},"Tao Zan, Professor, MD, PhD","+86 13795204523","zantao@sjtu.edu.cn",{"type":63,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100637371","phase-2-a-phase-ii-study-of-9mw3811-in-patients-with-pathological-scar-100637371",false,"NCT07576608","A Phase II Study of 9MW3811 in Patients With Pathological Scar","A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Properties, and Preliminary Efficacy of 9MW3811 in Patients With Pathological Scar","Inclusion Criteria:\n\n* Age ≥18 years\n* Pathological scar with no spontaneous regression over the prior 6 months\n* At least one scar with modified Vancouver Scar Scale (mVSS) score ≥9\n* Willing to use effective contraception for 6 months after last dose (if of childbearing potential)\n* Provide written informed consent\n\nExclusion Criteria:\n\n* Contracture scar causing deformity\n* All eligible scars either \\>10 cm in length and \\>5 cm in width, or located exclusively on sun-exposed areas (head, face, hands)\n* Evidence of scar infection or active systemic infection requiring treatment\n* Use of anti-scar medications (e.g., corticosteroids, immunosuppressants) or anti-scar procedures (surgery, laser, radiation, etc.) within 4 weeks prior to first dose\n* Prior treatment with IL-11 cytokine or IL-6 family targeted therapy (e.g., tocilizumab) within specified washout periods\n* Participation in another interventional study within 28 days\n* Positive serology for HBV, HCV, HIV, or syphilis with clinical significance\n* History of severe allergy or known hypersensitivity to study drug components\n* Clinically significant laboratory abnormalities (eGFR \\\u003C90 mL\u002Fmin\u002F1.73m², PLT \\\u003C100×10⁹\u002FL, QTc \\>450\u002F470 ms, bilirubin \\>1.5×ULN, AST\u002FALT \\>1.5×ULN)\n* Alcohol or drug abuse within 1 year\n* Pregnancy, breastfeeding, or unwillingness to use contraception\n* Any other condition that, in the investigator's judgment, would compromise subject safety or study compliance","ALL","18 Years",{"count":74,"type":75},30,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","This is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of 9MW3811 in patients with pathological scar.",[81],"Scar","2026-04-30",{"date":84,"type":85},"2026-05-08","ACTUAL",{"date":87,"type":85},"2025-12-29",{"date":89,"type":75},"2026-12",{"name":5,"class":6},1]